



SymBio Pharmaceuticals Limited  
San-Ei Building, 5-23-7 Shimbashi, Minato-ku, Tokyo 105-0004, Japan  
Tel: +81-3-5472-1125 Fax: +81-3-5472-3054 <http://www.symbiosis.co.jp/>

July 17, 2008

SymBio Pharmaceuticals Limited

Fuminori Yoshida

Representative Director, President and Chief Executive Officer

## **SymBio Completes Phase I Clinical Trials of Sustained-Release Transdermal Patch Containing Granisetron for Chemotherapy Induced Nausea and Vomiting.**

TOKYO, July 17, 2008 - SymBio Pharmaceuticals announces the completion of its Phase I study of SyB D-0701, the transdermal patch containing granisetron currently under development by the company. The Phase I study consists of two studies: one for safety and pharmacokinetics in Japanese subjects, and the other to confirm further safety in a local skin irritation study by investigating solar urticaria and phototoxicity. The final study report will be completed this fall. SymBio Pharmaceuticals will complete a comprehensive assessment based on the results of the two studies. SymBio plans to initiate a Phase II clinical study in cancer patients in the first half of 2009.

The original licensor, Abeille Pharmaceuticals, Inc., has received Special Protocol Assessment (SPA) from US FDA and plans to start its Phase III clinical study in the U.S. in August, 2008.

SyB D-0701 is a sustained-release transdermal patch containing the 5-HT<sub>3</sub> antagonist, granisetron, as an active ingredient which reduces nausea and vomiting in patients (CINV) undergoing treatment with cancer chemotherapies.

Unlike conventional injection or oral type anti-emetics, SyB D-0701 is a sustained-release transdermal patch with an anti-emetic effect that is sustained for over 120 hours. Thus, SyB D-0701 is expected to bring significant benefits to patients as supportive care, and to improve overall QOL (Quality of Life) of future chemotherapy patients as cancer prevalence continues to rise globally.

[Company Profile]

### **About SymBio Pharmaceuticals Limited**

SymBio Pharmaceuticals Ltd. was established in March 2005 by Fuminori Yoshida, who previously served as both Corporate VP of Amgen Ltd. and President of Amgen Japan, with the corporate mission of addressing underserved therapeutic areas having high medical need in Japan, Korea, Taiwan and other Asia Pacific Rim countries. SymBio's main focus lies in the development of drugs within three therapeutic areas: oncology, hematology and autoimmune disease. Through its proprietary in-house search and evaluation process and experienced management team with strong development expertise in biopharmaceuticals, SymBio is able to implement unique strategies in the development of drug candidates, thereby bringing much-needed therapies to market in an expeditious manner.

### **About Abeille Pharmaceuticals**

Abeille Pharmaceuticals, Inc. is a privately-held pharmaceutical company based in Princeton, New Jersey. The Company is focused on the formulation of products by applying advanced delivery technologies to existing drugs. These advanced delivery technologies include oral controlled release and transdermal delivery systems. The new products may benefit patients by requiring a lower dose of medicine, reduced side effects and easier administration of medication, thereby encouraging a patient to use the medication as prescribed. Abeille is dedicated to the development and commercialization of products that address unmet medical needs and improve the quality of life for patients. The Company's initial focus will be on drugs used to treat oncology related discomforts (such as CINV), diabetes and metabolic disorders, and CNS.

For further information, please contact:

**SymBio Pharmaceuticals Limited.**

**Osamu Ogawa, Ph.D.**

**Board Director, Senior Corporate Officer,**

**Senior Director, Research & Development**

**Tel: +081(0)3 5472 1127**

**E-mail: Please send your inquiry through "INQUIRY" in our homepage**

**URL:<http://www.symbiosis.co.jp>**